SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Lifecore Biomedical, Inc. (NASDAQ: LFCR) securities between October 7, 2020 and March 19, 2024. Lifecore operates as an integrated contract development and manufacturing organization in the U.S. and internationally. The Company purportedly designs, develops, manufactures, and sells differentiated products for biomaterial ...

Core Viewpoint - Lifecore Biomedical, Inc. is facing a class action lawsuit due to significant financial reporting issues, leading to a substantial drop in stock price and investor losses [3][4]. Group 1: Class Action Details - The class action is on behalf of investors who acquired Lifecore securities between October 7, 2020, and March 19, 2024, with a deadline to file a lead plaintiff motion by September 27, 2024 [1][6]. - Investors who suffered losses can inquire about pursuing claims under federal securities laws [2][6]. Group 2: Financial Reporting Issues - Lifecore's Audit Committee announced that previous financial statements for fiscal years 2022, 2021, and part of 2020 are no longer reliable and will require restatement due to errors in capitalized interest calculation, inventory valuation, and adjustments related to divested businesses [3][4]. - Following this announcement, Lifecore's stock price fell by $2.18, or 30.3%, closing at $5.01 per share on March 20, 2024, indicating significant investor injury [3]. Group 3: Allegations Against Defendants - The complaint alleges that Lifecore's management made materially false and misleading statements and failed to disclose adverse facts about the company's operations and financial health [4]. - Specific allegations include deficient internal controls over financial reporting, ineffective remediation efforts, and overstated financial position and prospects [4].

SAN DIEGO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR). If you incurred significant losses and want to act as the lead plaintiff in the Lifecore class action lawsuit or determine if you are eligible to receive a potential recovery of your losses, please submit your details here: SUBMIT YOUR INFORMATION NOW CLASS PERIOD: Oct ...

NEW YORK, Aug. 2, 2024 /PRNewswire/ -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ: LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore ...

NEW YORK, Aug. 02, 2024 (GLOBE NEWSWIRE) -- __________________ WHY: Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024. Lifecore describes itself as an "integrated contract development and manufacturing organization in the U.S. and internationally." A class action lawsuit has already been filed. If you wish to serve as lead plainti ...

NEW YORK, Aug. 1, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024. Lifecore describes itself as an "integrated contract development and manufacturing organization in the U.S. and internationally." A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Co ...

LOS ANGELES, Aug. 1, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ: LFCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Per ...

SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Lifecore Biomedical, Inc. (NASDAQ: LFCR) securities between October 7, 2020 and March 19, 2024, both dates inclusive (the "Class Period"), have until September 27, 2024 to seek appointment as lead plaintiff of the Lifecore Biomedical class action lawsuit. Captioned Carew v. Lifecore Biomedical, Inc., No. 24-cv-03028 (D. Minn.), the Lifecore Biomedical class action lawsuit charges Lifecore ...

NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR) in the United States District Court for the District of Minnesota on behalf of all persons and entities who purchased or otherwise acquired Lifecore securities between October 7, 2020 and March 19, 2024, both dates inclusive (the "Class Period"). Investo ...

NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the securities of Lifecore Biomedical, Inc. ("Lifecore") (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"). For more information, submit a form at Lifecore Biomedical, Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@ber ...